Clinical Trial Update: Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating Endostar in combination with chemotherapy for advanced non-small cell lung cancer and its impact on tumor angiogenesis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• Endostar (recombinant human endostatin)

Snippet

Sponsor: Xijing Hospital | Conditions: Lung Neoplasms | Phase 3 | Status: UNKNOWN